Shares of Keymed Biosciences (HKEX: 02162) are soaring 5.17% in Thursday's trading session, following the release of the company's impressive 2024 annual results and pipeline updates. The biotechnology firm's stock price surge reflects investor optimism about its strong product performance and advancement in clinical trials across multiple therapeutic areas.
A key highlight from the annual report is the successful launch and sales performance of Stapokibart (CM310), an IL-4Rα antibody. The drug, approved for multiple indications including atopic dermatitis, chronic rhinosinusitis with nasal polyposis, and seasonal allergic rhinitis, generated approximately RMB40 million in revenue within just three and a half months of its launch. This rapid market penetration demonstrates the drug's strong commercial potential and addresses significant unmet medical needs.
Keymed Biosciences also reported substantial progress across its diverse pipeline. Notably, the company's partnered Claudin 18.2 ADC (CMG901/AZD0901) with AstraZeneca is advancing in multiple clinical trials for various cancer indications. Additionally, other pipeline candidates such as CM313 (CD38 antibody), CM512 (TSLP x IL-13 bispecific antibody), and CM336 (BCMAxCD3 bispecific antibody) have shown promising results in their respective clinical studies. The company's focus on innovative therapies in oncology, immunology, and neurology has clearly resonated with investors, contributing to the stock's upward momentum.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。